January, 2022 - Microbiome Times Magazine

Publication of ECOSPOR lll Phase 3 Study Data Evaluating SER-109 in Recurrent C. Difficile Infection

January 24, 2022 Microbiome Times

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced the publication in the New England Journal of Medicine (NEJM) of data from its Phase 3 ECOSPOR III study evaluating SER-109, an investigational […]

Viruses and game theory

January 13, 2022 Microbiome Times

A new study from Tel Aviv University has found that, just like humans with Game Theory, viruses called bacteriophages (or phages) weigh all options and finally make an informed decision – whether the time has […]